Next Article in Journal
Corporate Social Responsibility Performance, Disclosure and Assurance: Introduction to the Special Issue of Administrative Sciences
Previous Article in Journal
Managing Your Brand for Employees: Understanding the Role of Organizational Processes in Cultivating Employee Brand Equity
Article Menu
Issue 3 (September) cover image

Export Article

Open AccessArticle
Adm. Sci. 2018, 8(3), 53; https://doi.org/10.3390/admsci8030053

The Middle East and Africa Code of Promotional Practices in the Pharmaceutical Industry

1
Dual Studies Business Administration Program, Faculty of Business and Economics, Al-Quds University, Abu Dis 20002, Palestine
2
Thammasat Business School, Tha Prachan, Bangkok 10200, Thailand
*
Author to whom correspondence should be addressed.
Received: 18 August 2018 / Revised: 3 September 2018 / Accepted: 7 September 2018 / Published: 10 September 2018
Full-Text   |   PDF [1111 KB, uploaded 10 September 2018]   |  

Abstract

The pharmaceutical industry is known for investing heavily in promotions targeted at healthcare professionals (HCPs). Governments around the world try to regulate unwanted promotional practices in different ways. Where binding laws are in place in the U.S.A., European governments favor self-regulation. The purpose of this research is the evaluation of the Middle East and Africa Code of Promotional Practices (MEACPP) as a preliminary draft and its implications. Our paper fills a research gap by looking into the perceptions of the parties involved, analyzing their interests, and predicting possible outcomes. We used a mixed-method approach. Interviews were conducted with pharmaceutical companies and associations; while a questionnaire was administered to HCPs. Our findings suggest that all parties are in favor of more transparency. However, when it comes to disclosing the received financial support, the HCPs are hesitant. An estimated 20% would be willing to fully disclose their received benefits, which is in line with their European colleagues. Multinational pharmaceutical companies follow their own in-house standards and fear being at a competitive disadvantage when local companies can promote their drugs without any strings attached. MEA pharmaceutical companies do not see the potential benefits of analyzing the publicly available data to identify key opinion leaders (KOLs). The limitation of our research is the fact that the MEACPP has not been implemented yet and survey results are therefore based on expectations rather than real events. View Full-Text
Keywords: Middle East and Africa Code of Promotional Practices; pharmaceutical industry; transparency code; self-regulation Middle East and Africa Code of Promotional Practices; pharmaceutical industry; transparency code; self-regulation
Figures

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).
SciFeed

Share & Cite This Article

MDPI and ACS Style

Salhout, S.; Bechter, C. The Middle East and Africa Code of Promotional Practices in the Pharmaceutical Industry. Adm. Sci. 2018, 8, 53.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Adm. Sci. EISSN 2076-3387 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top